Registration is open for our 2026 Annual General Meeting
RegisterView
This morning we announced results from our exploratory human Quicksome™ testosterone study, and I am pleased to share why I believe this work represents an important step for the Company.
Up to 32.5% more special-grade yield and 27.6% more total yield versus control. The independently designed and conducted Brazilian trial showed the strongest Agrarius program adding 8.0 tonnes per hectare in the higher-value 45 to 70 mm category, lifting special-grade share to about 80.7% of total yield versus 76.4% in the control.
This morning, we announced the completion of our corporate name change from Mountain Valley MD to The More Life Company.
This morning we announced the appointment of five additional advisors to MVMD,
Quicksome™ Technology and the Emerging Peptide Opportunity
MVMD enters 2026 positioned to convert validated progress across nutraceuticals, agriculture, and husbandry into disciplined, science-backed commercial growth through focused execution and responsible capital allocation.
Agrarius Commercial Progress
This morning, we released a formal business update media release summarizing some of MVMD’s key advancements over the first half of the year.
Agrarius™ is entering a pivotal commercialization phase, backed by successful global trials and strong market demand for sustainable agricultural solutions.
MVMD CEO, Dennis Hancock, shares a Year-End Business Update
Over the past six months, MVMD has experienced transformative progress across our three main business lines, demonstrating the differentiation and positive reception of our technologies in the marketplace.
MVMD has acquired the exclusive license and distribution rights for the Agrarius™ technology across Canada and the USA, Mexico, South America, Central America, and the Caribbean. We will also retain our global non-exclusive rights outside of this exclusive territory.
MVMD President and CEO, Dennis Hancock, provides commercialization progress update.
It's been one year since I shared with our shareholders that MVMD was commencing our transition from an R&D-focused biotech start-up business into a commercially focused biotech entity.
Watch MVMD's 2023 AGM hosted on September 28th, 2023
MVMD Business Update by Dennis Hancock, President & CEO of MVMD.
MVMD executes license agreement, related studies, and patent expansion for Soluvec™
MVMD Business Progress Update Video
MVMD Welcomes Dr. Elizabeth Norton to Advisory Role / Cold Chain and Vaccine Progress
Register for MVMD AGM – Wednesday, September 29th
The addition of Gokul Kannan and Mark Gelnaw to the MVMD team is expected to bring significant value as we continue to advance our key oncology and technology initiatives.
MVMD Update: FDA, Oncology, Cold Chain, Husbandry and more
Mike Farber and Steve Darling from Proactive Investor discussed MVMD's new water-solubilized selamectin breakthrough
MVMD Files for a new, novel dose sparing patent for IPV Polio
Tell us a little about your organization and what you are interested in exploring.